Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

Item

http://www.wikidata.org/entity/Q36443768

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@ast

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@en

type

Item

label

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@ast

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@en

prefLabel

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@ast

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@en

P1476

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

@en

P2093

Michel P Hermans

http://www.w3.org/2001/XMLSchema#string

P2860

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constitute

Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

P304

307-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040622311413952

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Charles Fruchart

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23251757

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

P932

3513890

http://www.w3.org/2001/XMLSchema#string